After a phase 3 push the livmoniplimab plan falters.
ApexOnco Front Page
Recent articles
The company discontinues one of its two KRAS G12D degraders.
The same trial that sent Summit up 272% sees the stock crash 36%.
Data in HER2-mutated NSCLC still look good, and studies in HER2-amplified tumours continue.
But half the responses with the KRAS G12D inhibitor zoldonrasib are unconfirmed.
But the company is awaiting pivotal results with TAR-200 in papillary disease before filing.
But sasanlimab's use looks set to remain narrow.
The curtain lifts on Veritac-2, rusfertide, and another double plenary for Astra.
